glp-1 drugs in development What is the pipeline for future medications for obesity? GLP-1 Receptor Agonist Market Size
Description
The hypoglycaemic effect of GLP-1RAs is achieved by stimulating insulin secretion in pancreatic cells, suppressing glucagon secretion in pancreatic cells, and slowing gastric emptying
A meta-analysis [74] including the ELIXA [66], LEADER [44], SUSTAIN-6 [67], EXSCEL [68], REWIND [70], and AMPLITUDE-O [51] studies found that GLP-1RAs were associated with better renal outcomes: a 30% or 40% or more decrease in glomerular filtration rate, need for renal replacement therapy, end-stage renal failure, or death from kidney disease by 21%
13.7% [press release]
When compared to other antihyperglycemic agents, patients with type 2 diabetes receiving GLP-1RAs therapy exhibit a lower risk of developing colorectal cancer [45]
Companies including Pfizer, Eli Lilly, and Structure Therapeutics are leading the charge in developing novel orals
